254 - Yttrium-90 Radioembolization for Treatment of Uveal Melanoma Liver Metastasis: A Meta-Analysis

Tuesday, April 14, 2026

4:12 PM - 4:21 PM ET

Presenting Author(s)

KD

Khari Derrick

Medical Student
University of Chicago, United States

Author/Co-author(s)

Qian Yu, MD (he/him/his)

Resident
University of Chicago, United States
Ed

Elise de Bruyn, MD

PGY4 IR-Integrated Resident
University of Chicago, United States
AK

Abdul Khan, MD

Resident Physician
University of Arizona, United States
Rakesh C. Navuluri, MD, FSIR

Associate Professor
University of Chicago, United States
Steven Zangan, MD

Associate Professor
University of Chicago, United States
TV

Thuong Van Ha, MD

Professor
University of Chicago, United States

Purpose: Uveal melanoma frequently metastasizes to the liver, where prognosis remains poor and systemic therapies have shown limited benefit. Small cohort studies have suggested that yttrium-90 (Y90) radioembolization is a feasible liver-directed therapy in this setting. This meta-analysis aims to evaluate the safety and effectiveness of Y90 radioembolization for the treatment of liver metastases from uveal melanoma.

Materials and Methods: A systematic literature review and meta-analysis were conducted using a random-effects model, including studies published up to March 2025. The following keywords were used: “uveal melanoma,” “uveal neoplasm,” “yttrium,” “radioembolization,” and "selective internal radiation therapy.” Data extracted included publication year, geographic region, sample size, study design, tumor burden, administered radioactivity, prior treatments, median survival time (MST), follow-up duration, adverse events, and radiographic response.

Results: Fifteen studies comprising a total of 292 patients were included. Based on Response Evaluation Criteria in Solid Tumors (RECIST), the pooled overall response rate (ORR) was 22.4% (95% confidence interval [CI], 12.8-31.9%; I² = 81.7%, p< 0.001), and the disease control rate (DCR) was 96.2% (95% CI, 50.6-87.7%; I² = 94.1%, p< 0.001). Using modified RECIST criteria (mRECIST), the pooled ORR was 44.3% (95% CI, 30.5-58.1%; I² = 12.0%, p=0.321), while the DCR was 79.5% (95% CI, 69.0-90.0%; I² < 0.1%, p=0.468). Hepatic progression-free survival (hPFS) following radioembolization ranged from 4.3 weeks to 15 months, and overall PFS ranged from 3‒6.6 months. MST following radioembolization ranged from 2.8‒46.6 months. The cumulative major adverse event rate related to radioembolization was 5.4% (95% CI, 1.5-29.3%; I² = 29.8%, p=0.153). Reported events included grade ≥3 hepatic toxicity (n=10), gastric ulcer (n=2), intraprocedural vessel dissection (n=2), severe abdominal pain (n=2), radiation cholecystitis (n=3), and enterocolitis (n=1).

Conclusion: Y90 radioembolization appears to be an effective treatment for liver metastases from uveal melanoma, demonstrating high response rates and favorable survival outcomes.